middle.news
Syntara Doses First Patient in Promising Anti-Scar Drug Trial
9:46am on Tuesday 29th of July, 2025 AEST
•
Healthcare
Read Story
Syntara Doses First Patient in Promising Anti-Scar Drug Trial
9:46am on Tuesday 29th of July, 2025 AEST
Key Points
First participant dosed in Phase 1a/b trial of SNT-9465
Trial to assess safety, tolerability, and efficacy in hypertrophic scars
SNT-9465 designed as a daily topical treatment to replace invasive therapies
Results due H1 2026 to support FDA Investigational New Drug application
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE